Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-337395 Bioavailability, Food-Effect, and Safety Study
NCT06270511Phase 1Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Mar 2024
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of S-337395 in respiratory syncytial virus infection (RSV) (3 arms), sponsored by Shionogi & Co., Ltd. Primary endpoints: Part A: Plasma Concentration of S-337395 and Part B: Number of Participants Experiencing Treatment-emergent Adverse Events. Started Mar 2024; status: completed.
02
Drugs
S-337395
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06270511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06270511.